

## DAFTAR PUSTAKA

1. Fajriansyah, Tahir H, Kombong A. Kajian Drug Relation Problem (DRPs) Kategori Interaksi Obat, Over Dosis dan Dosis Subterapi pada Pasien Gagal Jantung Kongestif di RSUP Universitas Hasanuddin. *J Ilm Farm.* 2016;5(1):2302–493.
2. Siswanto, Bambang Budi. Penyakit Kardiovaskular (PKV). 1st ed. Jakarta: Badan Penerbit FK UI; 2016. 269 p.
3. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). Hari Jantung Sedunia (World Heart Day): Your Heart is Our Heart Too. 2019.
4. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. *J Am Coll Cardiol.* 2013;62(16):1495–539.
5. Yancy CW. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *J Am Coll Cardiol.* 2017;
6. Bertram G. Katzung. Drugs Used in Heart Failure. In: *Basic and Clinical Pharmacology.* 14th ed. New York: McGraw-Hill Education; 2018. p. 212.
7. Kemenkes RI. Situasi Kesehatan Jantung. *Pus data dan Inf Kementerian Kesehat RI.* 2014;3.
8. Slatzberg MT. 2016 Update to Heart Failure Clinical Practice Guidelines. *J Am Coll Cardiol.* 2016;
9. DiPiro JT, Wells BG, Schwinghammer TL, Cecily V. DiPiro. *Pharmacotherapy Handbook.* Edisi 10. New York: McGraw-Hill; 2017.
10. Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus: Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies. *Circ Res.* 2019;124(1):121–41.
11. Kasznicki J, Drzewoski J. Heart failure in the diabetic population – pathophysiology, diagnosis and management. *Arch Med Sci.* 2014;10:546–

56.

12. Correale M, Paolillo S, Mercurio V, Limongelli G, Barilla F, Ruocco G, et al. Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. *Eur J Intern Med.* 2020;71(March):23–31.
13. Mariam S. Evaluasi Kejadian Interaksi Obat pada Pasien Rawat Inap Geriatri Penderita Gagal Jantung. *J Farmamedika.* 2016;1(1):28–33.
14. Utami P, Cahyaningsih I, Setiawardani RM. Identifikasi Drug Related Problems (DRPs) pada Pasien Congestive Heart Failure (CHF) di Rumah Sakit Periode Januari-Juni 2015. *J Farm Sains dan Prakt.* 2018;IV(1):37–43.
15. Aslam M. *Farmasi Klinis (Clinical Pharmacy): Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien.* Jakarta: PT Elex Media Komputindo; 2003.
16. Siregar. *Farmasi Klinik: Teori dan Penerapan.* Jakarta: Penerbit Buku Kedokteran EGC; 2006.
17. Kementerian Kesehatan Republik Indonesia. Modul Penggunaan Obat Rasional Dalam Paktek. Modul Pengguna Obat Rasional. 2011;3–4.
18. Ramdhani NSK. *Kajian Penggunaan Obat Antihipertensi Pada Pasien Gagal Jantung Kongestif di Irna Penyakit Dalam 2016, RSUP.* DR. M. Djamil Padang. Universitas Andalas; 2016.
19. Fikma AW. *Evaluasi Penggunaan Obat pada Pasien Gagal Jantung Kongestif di Poliklinik Jantung RSUP Dr.M. Djamil Padang.* Universitas Andalas; 2019.
20. Departemen Kesehatan RI. *Profil Kesehatan Indonesia.* Jakarta; 2008.
21. Underwood JC. *Patologi Umum dan Sistemik.* 2nd ed. Jakarta: EGC; 1999.
22. Price SA, Wilson, ML. *Patofisiologi: Konsep Klinis Proses-Proses Penyakit.* Edisi 6. Jakarta: EGC; 2005.
23. Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. *Circ Res.* 2018;122(4):624–38.
24. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). *Pedoman*

- Tata Laksana Gagal Jantung. Pertama. Jakarta; 2015.
25. Ardiansyah M. Medikal Bedah Untuk Mahasiswa. Yogyakarta: Diva Press; 2012.
  26. Bustan MN. Manajemen Pengendalian Penyakit Tidak Menular. Jakarta: PT Rineka Cipta; 2015.
  27. Lüscher TF. Risk factors for and management of heart failure. *Eur Heart J*. 2015;36(34):2267–9.
  28. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. *Arch Intern Med*. 2001;161(7):996–1002.
  29. Hellermann JP, Goraya TY, Jacobsen SJ, Weston SA, Reeder GS, Gersh BJ, et al. Incidence of heart failure after myocardial infarction: Is it changing over time? *Am J Epidemiol*. 2003;157(12):1101–7.
  30. Mann DL, Libby P, Bonow RO, ZD Braunwald. *Braunwald Heart Disease A Textbook of Cardiovascular Medicine*. 8th ed. USA: Elsevier Saunders; 2007.
  31. Lip GYH, Gibbs CR, BD. Angioedema due to ACE Inhibitors: increased risk in patients of African origin. *Br J Clin Pharmacol*. 2002;48:861–5.
  32. Cowie MR, P-WP. Pathophysiology of Heart Failure. In: *Essential Cardiology*. 2nd ed. New York: Springer; 2013.
  33. Lee DS, Massaro JM, Wang TJ, Kannel WB, Benjamin EJ, Kenchaiah S, et al. Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life. *Hypertension*. 2007;50(5):869–76.
  34. Chaplin S. Chronic Heart Failure in Adults: Diagnosis and Management. *Prescriber*. 2019;30(1):16–8.
  35. Gilman G&. *Dasar Farmakologi Terapi*. Jakarta: Penerbit Buku Kedokteran EGC; 2006.
  36. Setiawati, Nafrialdi. *Farmakologi dan Terapi*. 5th ed. Jakarta: Departemen Farmakologi dan Terapi Fakultas Kedokteran Universitas Indonesia; 2007.
  37. Lehrke M, Marx N. Diabetes Mellitus and Heart Failure. *Am J Med*. 2017;130(6):S40–50.
  38. Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A et

- al. Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia. Pengurus Besar PERKENI; 2015.
39. Rosano GM, Vitale C, Seferovic P. Comorbidities Heart Failure in Patients with Diabetes Mellitus Heart Failure in Diabetes Mellitus. 2017;52–5.
  40. Edi Tarigan TJ. Buku Ajar Ilmu Penyakit Dalam. edisi keen. Setiati S, Alwi I, Sudoyo AW, K. MS, editors. InternaPublishing. 2014.
  41. Dharma S. Buku Ajar Praktis Patofisiologi, Farmakologi dan Farmakoterapi. Padang: Gre Publishing; 2019.
  42. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Indonesia Nomor 72 Tahun 2016. Jakarta: Menteri Kesehatan Republik Indonesia; 2016.
  43. American Society of Health-System Pharmacists. ASHP Guidelines on Medication-Use Evaluation. *Am J Heal Syst Pharm*. 1986;53:220–2.
  44. Mariam AH, Raghavendra Y, Bobasa EM. Evaluating Rational Drug Use with the help of World Health Organization's core indicators in Bule Hora Hospital, Southern Ethiopia. *Gaziantep Med J*. 2015;21(2):108–13.
  45. Shivhare S, Kunjwani H, Manikrao A, Bondre A. Drugs hazards and rational use of drugs: A review. *J Chem Pharm Res*. 2010;2(1):106–12.
  46. Ofstad AP, Atar D, Gullestad L. The Heart Failure Burden of Type 2 Diabetes Mellitus—A Review of Pathophysiology and Interventions. 2018;23:303–23.
  47. Harigustian Y, Arlina Dewi A, Khoiriyati. Gambaran Karakteristik Pasien Gagal Jantung Usia 45 – 65 Tahun di Rumah Sakit PKU Muhammadiyah Gamping Sleman. *Indones J Nurs Pract*. 2016;1.
  48. Pepine CJ, Merz CNB, El Hajj S, Ferdinand KC, Hamilton MA, Lindley KJ, et al. Heart failure with preserved ejection fraction: Similarities and differences between women and men. *Int J Cardiol*. 2020;304:101–8.
  49. Hou N, Chui MA, Eckert GJ, Oldridge NB, Murray MD, Bennett SJ. Relationship of Age and Sex to Health-Related Quality of Life in Patients with Heart Failure. *Am J Crit Care*. 2004;13(2):153–61.
  50. Karavidas A, Lazaros G, Tsiachris D, Pyrgakis V. Aging and the

- Cardiovascular System. *Hell J Cardiol.* 2009;51:421–7.
51. Azhari DL. Evaluasi Penggunaan Digoksin pada Pasien Gagal Jantung di Instalasi Rawat Inap Pusat Jantung RSUP Dr. M. Djamil Padang. Universitas Andalas; 2017.
  52. Ai Yeyeh Rukiyah, Yulianti L. Asuhan Kebidanan IV (Patologi Kebidanan). Jakarta: Trans Info Media; 2010.
  53. Catalona WJ. Effect of Enalapril on Survival in Patient with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. *N Engl J Med.* 1991;329(14):977–86.
  54. Goodman & Gilman. Farmakoterapi Gagal Jantung Kongestif. In: Manual Farmakologi dan Terapi. Jakarta: EGC; 2010. p. 525.
  55. Guyton A., Hall J. Buku Ajar Fisiologi Kedokteran. Jakarta: EGC; 2008.
  56. Rampengan SH. Peran Terkini Beta-Bloker pada Pengobatan Kardiovaskular. Jakarta: Badan Penerbit Fakultas Kedokteran UI; 2014.
  57. Safi S, Korang SK, Nielsen EE, Sethi NJ, Feinberg J, Gluud C, et al. Beta-blockers for heart failure ( Protocol ), Cochrane Database of Systematic Reviews Beta-blockers. 2017;
  58. Ali Ghanie. Tatalaksana Gagal Jantung Kronik. Div Kardiologi Bagian Ilmu Penyakit Dalam FK UNSRI. 2009;
  59. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2016;37(27):2129-2200m.
  60. Almasdy D, Sari DP, Suhatri S, Darwin D, Kurniasih N. Evaluasi Penggunaan Obat Antidiabetik Pada Pasien Diabetes Melitus Tipe-2 di Suatu Rumah Sakit Pemerintah Kota Padang – Sumatera Barat. *J Sains Farm Klin.* 2015;2(1):104.
  61. Soewondo P, Soegondo S, Suastika K, Pranoto A, Soeatmadji DW. The DiabCare Asia 2008 study – Outcomes on Control and Complications of Type 2 Diabetic Patients in Indonesia. 2010;19(4):235–44.
  62. Tarigan TJE, Yunir E, Subekti I, Pramono LA, Martina D. Profile and Analysis of Diabetes Chronic Complications in Outpatient Diabetes Clinic

- of Cipto Mangunkusumo Hospital , Jakarta. 2015;24(3):156–62.
63. Direktorat Bina Farmasi Komunitas dan Klinik, Kesehatan DJBK dan A. Pharmaceutical Care untuk Penyakit Diabetes Mellitus. 2005.
  64. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. *J R Soc Med.* 2001;94(8):378–83.
  65. Whellan DJ, Zhao X, Hernandez AF, Liang L, Peterson ED, Bhatt DL, et al. Predictors of Hospital Length of Stay in Heart Failure: Findings From Get with the Guidelines. *J Card Fail.* 2011;17(8):649–56.
  66. Capell F, Colet C, Mirallens D, Saladich G. Trends and Predictors of Hospitalization, Readmissions and Length of Stay in Ambulatory Patients with Heart Failure. *Rev Clin Esp.* 2013;213(1):1–7.
  67. Rohde, Clausell, Ribeiro, Goldraich, Netto, William. Health outcomes in decompensated congestive heart failure: a comparison of tertiary hospitals in Brazil and United States. *Int J Cardiol.* 2005;102.
  68. Kajimoto K, Sato N, Keida T, Mizuno M, Sakata Y A. Association between length of stay, frequency of in-hospital death, and causes of death in Japanese patients with acute heart failure syndromes. *Int J Cardiol.* 2013;168(1).
  69. Djaya KH, Nasution SA, Antono D. Gambaran Lama Rawat dan Profil Pasien Gagal Jantung di Rumah Sakit Cipto Mangunkusumo. *Indones J Crit Emerg Med.* 2015;2(4).
  70. Purnomo H, Syamsul ES. *Statistika Farmasi.* Yogyakarta: CV Grafika Indah; 2017.